People with rare genetic variants that lead to higher muscle mass do not have a higher risk of heart enlargement, heart failure, or abnormal heart structure based on cardiac MRI scans.
See the scientific wording
Rare myostatin gene variants associated with increased muscle mass are not significantly associated with an increased risk of hypertrophic cardiomyopathy, heart failure, or adverse changes in cardiac structure as assessed by cardiac MRI in a population of over 77,000 individuals.
Correlational — new studies may shift this
ObservationalOne moderate-quality study links this claim to the outcome, but causation is not established.
What the research says
1 study reviewedSupporting (1)
Cohort StudyHuman2026
People born with a rare gene change that makes their muscles bigger and fat less don’t have thicker hearts or more heart problems, even though they’re super muscular. So, drugs that block myostatin to build muscle probably won’t hurt the heart.
Contradicting (0)
No contradicting studies found yet
That doesn't mean it's settled — it just means no study has tested the opposite.
Quality-weighted scoring: we follow the GRADE framework — each study is rated High, Moderate, Low, or Very Low based on study design, methodology rigor, and risk of bias. A single high-quality RCT can outweigh several weaker observational studies.
Scores reflect study quality, not just count.
When the myostatin protein is disrupted, muscles grow larger because the signal that normally limits muscle growth is turned off. This increase in muscle does not cause the heart to thicken or become damaged, because the same signal does not control heart muscle growth in the same way. The heart responds differently to the absence of myostatin, so it stays normal even when skeletal muscles become much bigger.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting study
How Fit Body Science checks a claim
- 1
We isolate the claim
Health advice from videos, articles and studies is broken down into single, testable claims.
- 2
We find the research
Each claim is matched against peer-reviewed studies, with every source cited by DOI.
- 3
We grade the evidence
Studies are scored on methodology, statistical rigor, transparency and publication quality.
The fitness and health internet is full of confident claims. We check them against real research.
Every claim on this site is traced back to peer-reviewed studies, scored on methodology and reporting quality, and given a verdict you can audit yourself — sources, DOIs and all.
- Full evidence breakdown and mechanism chains
- Ask our AI anything about a claim or its studies
- Get notified when new research changes a verdict
People with rare genetic variants that lead to higher muscle mass do not have a higher risk of heart enlargement, heart failure, or abnormal heart structure based on cardiac MRI scans.
Mechanism
1 studyWhen myostatin doesn't work, muscles get bigger because the signal that stops them from growing is gone. The heart doesn't get bigger or damaged because it doesn't use myostatin to control its size. So, bigger muscles don't mean a weaker or thicker heart.
When the myostatin protein is disrupted, muscles grow larger because the signal that normally limits muscle growth is turned off. This increase in muscle does not cause the heart to thicken or become damaged, because the same signal does not control heart muscle growth in the same way. The heart responds differently to the absence of myostatin, so it stays normal even when skeletal muscles become much bigger.
Function-disrupting variants in the myostatin gene alter the structure of the myostatin precursor protein, preventing its proper maturation and secretion
Reduced levels of bioactive myostatin ligand decrease binding to ActRIIA/B and ALK4/5 receptors on skeletal muscle cells
De-repression of SMAD2/3 signaling in skeletal muscle enhances satellite cell activation, myoblast proliferation, and protein synthesis, leading to muscle hypertrophy
Increased skeletal muscle mass elevates systemic metabolic demand and shifts energy partitioning toward lean tissue, reducing adiposity
Cardiac muscle cells do not respond to myostatin loss with increased growth or fibrotic remodeling, maintaining normal wall thickness and chamber structure
Evidence from Studies
Supporting (1)
Community contributions welcome
People born with a rare gene change that makes their muscles bigger and fat less don’t have thicker hearts or more heart problems, even though they’re super muscular. So, drugs that block myostatin to build muscle probably won’t hurt the heart.
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Systematic Review of Rare Myostatin Variants and Cardiac Outcomes in Large Cohorts
Population: Adults with rare myostatin variants and matched controls; Intervention: None (observational); Comparator: Individuals without rare myostatin variants; Outcome: Incidence of hypertrophic cardiomyopathy, heart failure, and cardiac MRI-measured structural changes; Duration: Long-term follow-up across studies
Prospective Cohort Study of Myostatin Variant Carriers and Cardiac Events Over 10 Years
Population: Over 77,000 individuals genotyped for myostatin variants; Intervention: None; Comparator: Carriers vs non-carriers; Outcome: Incident hypertrophic cardiomyopathy, heart failure, and cardiac MRI changes; Duration: Minimum 5–10 years of follow-up
Cross-Sectional Analysis of Myostatin Variants and Cardiac MRI Findings in 77,000 Individuals
Population: 77,000 individuals with genotyping and cardiac MRI data collected simultaneously; Intervention: None; Comparator: Variant carriers vs non-carriers; Outcome: Prevalence of hypertrophic cardiomyopathy, heart failure, and cardiac MRI abnormalities; Duration: Single time point
Case-Control Study Comparing Myostatin Variant Frequency in Patients with Hypertrophic Cardiomyopathy vs Healthy Controls
Population: Cases with hypertrophic cardiomyopathy or heart failure confirmed by cardiac MRI; Controls: Matched individuals without cardiac disease; Intervention: None; Comparator: Variant frequency between groups; Outcome: Presence or absence of rare myostatin variants; Duration: Retrospective
In Vitro Analysis of Myostatin Variant Effects on Cardiomyocyte Growth and Structure
Population: Human induced pluripotent stem cell-derived cardiomyocytes engineered with rare myostatin variants; Intervention: Expression of variant vs wild-type myostatin; Comparator: Wild-type myostatin-expressing cells; Outcome: Cell size, sarcomere organization, and contractile function; Duration: Short-term culture (days to weeks)